These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30246595)

  • 1. Mortality during US FDA clinical trials in patients with diabetes, hypertension, depression and schizophrenia.
    Khan A; Fahl Mar K; Gokul S; Brown WA
    World J Biol Psychiatry; 2020 Jan; 21(1):64-71. PubMed ID: 30246595
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials.
    Khan A; Faucett J; Morrison S; Brown WA
    JAMA Psychiatry; 2013 Oct; 70(10):1091-9. PubMed ID: 23986353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.
    Khan A; Schwartz K; Stern C; Redding N; Kolts RL; Brown WA; Robinson DS
    J Clin Psychiatry; 2007 Dec; 68(12):1828-33. PubMed ID: 18162012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In-patient suicide -- a comparison of psychiatric in-patient suicides versus a control group of inpatients from the same treatment era without suicide].
    Wolfersdorf M; Klinkisch M; Franke C; Keller F; Wurst FM; Dobmeier M
    Psychiatr Prax; 2003 Jan; 30(1):14-20. PubMed ID: 12524578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia.
    Storosum JG; van Zwieten BJ; Wohlfarth T; de Haan L; Khan A; van den Brink W
    Arch Gen Psychiatry; 2003 Apr; 60(4):365-8. PubMed ID: 12695313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study.
    Olfson M; Marcus SC; Shaffer D
    Arch Gen Psychiatry; 2006 Aug; 63(8):865-72. PubMed ID: 16894062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective.
    Laughren TP
    Eur Psychiatry; 2001 Nov; 16(7):418-23. PubMed ID: 11728855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension.
    Piette JD; Heisler M; Ganoczy D; McCarthy JF; Valenstein M
    Psychiatr Serv; 2007 Feb; 58(2):207-12. PubMed ID: 17287377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuity of medication management in Medicaid patients with chronic comorbid conditions: An examination by mental health status.
    Farley JF; Hansen RA; Domino ME; Borse M; Mahendraratnam N; Ray N; Maciejewski ML
    Gen Hosp Psychiatry; 2017; 45():25-31. PubMed ID: 28274335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosed Mental Health Conditions and Risk of Suicide Mortality.
    Yeh HH; Westphal J; Hu Y; Peterson EL; Williams LK; Prabhakar D; Frank C; Autio K; Elsiss F; Simon GE; Beck A; Lynch FL; Rossom RC; Lu CY; Owen-Smith AA; Waitzfelder BE; Ahmedani BK
    Psychiatr Serv; 2019 Sep; 70(9):750-757. PubMed ID: 31185853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clarke Institute experience with completed suicide: 1966 to 1997.
    Martin BA
    Can J Psychiatry; 2000 Sep; 45(7):630-8. PubMed ID: 11056825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports.
    Khan A; Schwartz K; Redding N; Kolts RL; Brown WA
    Neuropsychopharmacology; 2007 Nov; 32(11):2422-30. PubMed ID: 17314915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excess mortality and shortened life expectancy in people with major mental illnesses in Taiwan.
    Pan YJ; Yeh LL; Chan HY; Chang CK
    Epidemiol Psychiatr Sci; 2020 Aug; 29():e156. PubMed ID: 32792024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.
    Khan A; Warner HA; Brown WA
    Arch Gen Psychiatry; 2000 Apr; 57(4):311-7. PubMed ID: 10768687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial.
    Fleischhacker WW; Kane JM; Geier J; Karayal O; Kolluri S; Eng SM; Reynolds RF; Strom BL
    J Clin Psychiatry; 2014 Mar; 75(3):e184-90. PubMed ID: 24717389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is specific to suicide in schizophrenia disorder? Demographic, clinical and behavioural dimensions.
    McGirr A; Turecki G
    Schizophr Res; 2008 Jan; 98(1-3):217-24. PubMed ID: 17942279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US regional differences in death rates from depression.
    Polednak AP
    Soc Psychiatry Psychiatr Epidemiol; 2012 Dec; 47(12):1977-83. PubMed ID: 22526823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
    Doshi JA; Li P; Desai S; Marcus SC
    J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suicide risk analysis among patients assigned to psychotropics and placebo.
    Khan A; Kolts RL; Brodhead AE; Krishnan KR; Brown WA
    Psychopharmacol Bull; 2006; 39(1):6-14. PubMed ID: 17065970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.